Steve Silvestro brings more than 20 years of experience in direct operations, sales, and partner network growth, to lead revenue activities and strengthen the go-to-market.
Steve is responsible for driving OptimizeRx's platform revenue growth including enterprise-level direct-to-patient and direct-to-provider product adoption to improve patient outcomes.
During his tenure at Decision Resources Group, he was an instrumental leader in the growth of the company from $30 million to $180 million in revenue. His customer-first philosophy is greatly aligned to our values at OptimizeRx.
Steve previously served as vice president and general manager at CCH Tagetik, a division of Wolters Kluwer. Prior pharma leadership experience includes executive positions with Prognos, Decision Resources Group, and D.M.S. Silvestro has extensive channel expertise in biopharma commercialization, global market access, market research, analytics, enterprise SaaS solutions, and strategy.
Silvestro received a master’s degree in Business Management from Harvard University. He also holds undergraduate degrees from Brigham Young University in both Business and Italian. He is fluent in English, Italian, Spanish and conversational in French.
What is Stephen L. Silvestro's net worth?
The estimated net worth of Stephen L. Silvestro is at least $1.16 million as of October 3rd, 2025. Mr. Silvestro owns 188,916 shares of OptimizeRx stock worth more than $1,158,055 as of April 11th. This net worth evaluation does not reflect any other assets that Mr. Silvestro may own. Learn More about Stephen L. Silvestro's net worth.
How do I contact Stephen L. Silvestro?
Has Stephen L. Silvestro been buying or selling shares of OptimizeRx?
Who are OptimizeRx's active insiders?
Are insiders buying or selling shares of OptimizeRx?
During the last twelve months, insiders at the sold shares 3 times. They sold a total of 14,128 shares worth more than $243,615.68. The most recent insider tranaction occured on December, 19th when insider Edward Stelmakh sold 1,388 shares worth more than $18,751.88. Insiders at OptimizeRx own 5.6% of the company.
Learn More about insider trades at OptimizeRx. Information on this page was last updated on 12/19/2025.
